STOCK TITAN

Electrocore Stock Price, News & Analysis

ECOR Nasdaq

Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.

electroCore, Inc. (ECOR) is a leader in non-invasive vagus nerve stimulation therapies, providing innovative solutions for neurological conditions and wellness applications. This page serves as the definitive source for ECOR news, offering investors and professionals timely updates on regulatory developments, clinical research, and strategic initiatives.

Access curated press releases covering FDA clearances, partnership announcements, and financial results. Stay informed about advancements in gammaCore™ therapies for migraine treatment and TAC-STIM cognitive enhancement technologies. Our repository includes updates on international expansions, clinical trial outcomes, and product pipeline developments.

Bookmark this page for direct access to primary source materials from electroCore, including neuromodulation research breakthroughs and commercialization progress across healthcare and defense sectors. Regular updates ensure you maintain current awareness of ECOR's position in the evolving bioelectronic medicine landscape.

Rhea-AI Summary

electroCore (NASDAQ: ECOR) announced the issuance of U.S. Patent No. 11,191,953 by the USPTO, focused on treating symptoms of stroke and transient ischemic attack (TIA) through non-invasive electrical stimulation. This patent bolsters research in stroke treatment, a leading cause of death and disability globally. Earlier this year, the TR-VENUS study reported full enrollment for investigating non-invasive vagus nerve stimulation (nVNS) for acute stroke treatment. The patent aims to enhance the application of electroCore’s technology to mitigate stroke impacts, with ongoing trials expected to shed light on its efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
none
-
Rhea-AI Summary

electroCore, a bioelectronic medicine company (NASDAQ: ECOR), will host virtual one-on-one meetings at the Canaccord Genuity MedTech & Diagnostics Forum on November 18, 2021. The management team aims to discuss its non-invasive vagus nerve stimulation therapy platform designed for treating migraines and cluster headaches, including acute and preventive treatments. Stakeholders interested in a meeting should contact their Canaccord Genuity representative to arrange the details. For more information, visit www.electrocore.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
conferences
-
Rhea-AI Summary

electroCore reported third quarter 2021 revenue of $1.5 million, a significant increase of 17% sequentially and 38% year-over-year. The gross margin expanded to 76%, and cash reserves reached approximately $39.0 million. Despite a GAAP net loss of $4.0 million, the company announced reduced operating expenses and a confidence in growth prospects despite pandemic impacts on its markets. The company raised about $18.8 million through a public offering, ensuring sufficient funds for planned operations over the next year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.05%
Tags
Rhea-AI Summary

electroCore, Inc. (NASDAQ: ECOR) will report its financial results for Q3 2021 on November 4, 2021, following the market close. A conference call will be held at 4:30 PM ET to discuss the results. The company focuses on non-invasive vagus nerve stimulation therapies aimed at treating various neurological conditions including migraines and cluster headaches. With a commercial-stage product line, electroCore aims to improve patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.22%
Tags
-
Rhea-AI Summary

On October 20, 2021, electroCore, Inc. (Nasdaq: ECOR) announced a peer-reviewed study in the British Journal of Healthcare Management evaluating prescribing trends for gammaCore in treating cluster headaches in England from April 2019 to 2020. The study involved 655 patients, revealing that 46.3% continued treatment with at least one refill and 30.9% required two or more refills. This suggests a durable benefit of gammaCore's non-invasive vagus nerve stimulation (nVNS) therapy. The NHS’s reimbursement program and favorable cost-saving implications were also highlighted.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none
-
Rhea-AI Summary

electroCore has received an amended Medical Device License from Health Canada for gammaCore nVNS to treat migraine in adolescents aged 12-17. This expansion allows for both acute and preventive treatment of migraine, providing a non-drug option in a field with limited treatments for young patients. The decision is based on positive data, including a study showing 46.8% attack resolution without additional medication. The device is now available in Canada through RSK Medical Inc., enhancing options for managing primary headache disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
none
Rhea-AI Summary

electroCore, Inc. (Nasdaq: ECOR) anticipates approximately $1.5 million in revenue for Q3 2021, reflecting a 15% increase from the previous quarter and 36% growth year-over-year. The company reported net cash used for operations was around $3.5 million, with cash reserves reaching $39 million by September 30. Revenue from government channels was approximately $946,000, up from $779,000 in Q2 2021. International sales contributed $371,000. The company raised about $18.8 million through a public offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
none
-
Rhea-AI Summary

On September 30, 2021, electroCore, Inc. (NASDAQ: ECOR) announced the rescheduling of its presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference to the same day at 12:40 PM EDT. Investors interested in the presentation can register for the conference through the provided link. Following the event, a replay of the webcast will be available on the company's investor section of its website. electroCore focuses on bioelectronic medicine, particularly using non-invasive vagus nerve stimulation for treating various neurological conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
none
-
Rhea-AI Summary

On September 29, 2021, electroCore (Nasdaq: ECOR) released findings from the SAVIOR-1 study, which evaluated the use of non-invasive vagus nerve stimulation (nVNS) during COVID-19 treatment. Conducted in Spain, the study enrolled 110 patients and demonstrated significant reductions in inflammation biomarkers, specifically C-reactive protein and procalcitonin, among nVNS patients compared to controls. The therapy was well-tolerated, administered three times daily, and suggested potential benefits in managing COVID-19 symptoms. The manuscript is now available on MedRxiv and under peer review.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
Rhea-AI Summary

electroCore, a commercial-stage bioelectronic medicine company, announced its management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021, at 8:15 am EDT. The conference runs from September 27 to 30, 2021. Investors can register for the event HERE.. Additionally, the company will attend the MicroCap Rodeo: Fall Harvest Best Ideas Conference from October 5-8, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.28%
Tags
conferences

FAQ

What is the current stock price of Electrocore (ECOR)?

The current stock price of Electrocore (ECOR) is $6.11 as of July 3, 2025.

What is the market cap of Electrocore (ECOR)?

The market cap of Electrocore (ECOR) is approximately 40.1M.
Electrocore

Nasdaq:ECOR

ECOR Rankings

ECOR Stock Data

40.07M
5.26M
23.59%
12.63%
1.83%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
ROCKAWAY